Investors To Block Proposed Buyout Of China’s AsiaPharm
This article was originally published in PharmAsia News
Money manager investors in China's AsiaPharm Group plan to block a proposed acquisition by MBK Partners, a private-equity firm specializing in the Asia-Pacific region. The opposing money managers, who together own 10 percent of AsiaPharm stock, say the MBK offer of $257 million for the firm is too low. The MBK offer has the backing of AsiaPharm executives, who own a combined 44.1 percent of MBK shares. (Click here for more - a subscription may be required
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.